Showing results (361-370 of 422) with videos related to
Sort By:
Pageof 43
Plos Neglected Tropical Diseases|May 9, 2017
In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccinationStephen S Whitehead, Anna P Durbin, Kristen K Pierce, et al.Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic MalignanciesJason J Luke, Karen Gelmon, Lillian L Siu, et al.Medrxiv : the Preprint Server for Health Sciences|May 7, 2024
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanomaAlexandra Tompkins, Zane N Gray, Rebekah E Dadey, et al.Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.Journal of Virology|February 16, 2018
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph NodesSinthujan Jegaskanda, Rosemarie D Mason, Sarah F Andrews, et al.Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.Cancer|August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experienceJason J Luke, Margaret K Callahan, Michael A Postow, et al.Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.Pageof 43